Levodopa delivery systems: advancements in delivery of the gold standard

Bibliography

• Parkinson J. An essay on the shaking palsy. J Neuropsychiatry Clin Neurosci 2002;14:223-36
   PubMed Web of Science ®Google Scholar
• Kempster PA, Hurwitz B, Lees AJ. A new look at james parkinson's essay on the shaking palsy. Neurol 2007;69:482-5
   PubMed Web of Science ®Google Scholar
• Veazey C, Aki SOE, Cook KF, Prevalence and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2005;17:310-23
   PubMed Web of Science ®Google Scholar
• Brocks DR. Anticholinergic drugs used in Parkinson's disease: an overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharmaceut Sci 1999;2:39-46
   PubMed Web of Science ®Google Scholar
• Schapira AHV. Present and future drug treatment for Parkinson's disease. J Neurol Neurosurg Psych 2005;76:1472-8
   PubMed Web of Science ®Google Scholar
• Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psych 2008;79:368-76
   PubMed Web of Science ®Google Scholar
• Carlsson A, Lindqvist M, Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957;180:1200
   PubMed Web of Science ®Google Scholar
• Girault J, Greengard P. The neurobiology of dopamine signaling. Arch Neurol 2004;61:641-4
   PubMed Web of Science ®Google Scholar
• Thanvi BR, Lo TCN. Long term motor complications of L-dopa: clinical features, mechanisms, and management strategies. Postgrad Med J 2004;80:452-8
   PubMed Web of Science ®Google Scholar
• Björklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci 2007;30:194-202
   PubMed Web of Science ®Google Scholar
• Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in human brain. Their behaviour in extrapyramidal system diseases. (In German). Klin Wochenschr 1960;38:1236-9, Republished in English in Parkinsonism Relat Disord 1998;4:53-57
   PubMed Web of Science ®Google Scholar
• Cotzias CG, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-9
   PubMed Web of Science ®Google Scholar
• Gordon M, Markham J, Hartlein JM, Intravenous L-dopa administration in humans based on a two-compartment kinetic model. J Neurosci Methods 2007;159:300-7
   PubMed Web of Science ®Google Scholar
• Birkmayer W, Hornykiewicz O. Der l-3,4-dioxyphenylalanin (=DOPA)-Effekt bei parkinson-akinese. Wien Klin Wochenschr 1961;73:787-8
   PubMedGoogle Scholar
• Collister KA Albensi BC. Potential therapeutic targets in the NF-kappaB pathway for Alzheimer's disease. Drug News Perspect 2005;18:623-9
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Tyrosine hydroxylase replacement in experimental Parkinson's disease with extravascular gene therapy. NeuroRx 2005;2:129-38
   PubMedGoogle Scholar
• Tyler CM, Federoff HJ. CNS gene therapy and a nexus of complexity: systems and biology at a crossroads. Cell Transplant 2006;15:267-73
   PubMed Web of Science ®Google Scholar
• Kabanov AV, Gendelman HE. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Pol Sci (Polymers in Biomedical Applications) 2007;32:1054-82
   PubMed Web of Science ®Google Scholar
• Sandoval KE, Witt KA. Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol Dis 2008;32:200-19
   PubMed Web of Science ®Google Scholar
• Kordower JH, Goetz CG. The first miracle in neurodegenerative disease: the discovery of oral L-dopa. Brain Res Bull 1999;50:377-8
   PubMed Web of Science ®Google Scholar
• Fahn S. The history of dopamine and L-dopa in the treatment of Parkinson's disease. Mov Disord 2008;23:S497-508
   PubMed Web of Science ®Google Scholar
• Muzzi C, Bertocci E, Terzuoli L, Simultaneous determination of serum concentrations of L-dopa, dopamine, 3-O-methyldopa and alpha-methyldopa by HPLC. Biomed Pharmacother 2008;62:253-8
   PubMed Web of Science ®Google Scholar
• Okereke CS. Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson's disease patients experiencing motor fluctuations with L-dopa. J Pharm Pharm Sci 2002;5:146-61
   PubMed Web of Science ®Google Scholar
• Jankovic J. L-dopa strengths and weakness. Neurol 2002;58:S19-32
   PubMed Web of Science ®Google Scholar
• Kostoff RN, Briggs MB. Literature-Related Discovery (LRD): potential treatments for Parkinson's disease. Technol Forecast Soc Change 2008;75:226-38
   Web of Science ®Google Scholar
• Seeberger LC Hauser RA. Optimizing bioavailability in the treatment of Parkinson's disease. Neuropharmacol 2007;53:791-800
   PubMed Web of Science ®Google Scholar
• Nutt JG, Obeso JA, Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci 2000;23:S109-15
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Nyholm D. New developments in L-dopa therapy. Neurol 2004;62:9S-16
   PubMed Web of Science ®Google Scholar
• Stocchi F. Prevention and treatment of motor fluctuations. Parkinsonism Relat Disord 2003;9:73-81
   Web of Science ®Google Scholar
• Hsu AF, Han C-H. Oral disintegrating dosage forms. WO2006073729; 2006
   Google Scholar
• Pfeiffer RF. A promising new technology for Parkinson's disease. Neurol 2005;65:S6-10
   Google Scholar
• Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-87
   PubMed Web of Science ®Google Scholar
• Olanow WC. The scientific basis for the current treatment of Parkinson's disease. Ann Rev Med 2004;55:41-60
   PubMed Web of Science ®Google Scholar
• Poewe W. The role of COMT inhibition in the treatment of Parkinson's disease. Neurol 2004;62:31S-38
   PubMed Web of Science ®Google Scholar
• Palhagen S, Heinonen E, Hagglund J, ; the Swedish Parkinson Study Group. Selegiline slows the progression of the symptoms of Parkinson disease. Neurol 2006;66:1200-6
   PubMed Web of Science ®Google Scholar
• Melamed E, Offen D, Shirvan A, Ziv I. L-dopa–an exotoxin or a therapeutic drug? J Neurol 2000;247:II135-II139
   PubMed Web of Science ®Google Scholar
• Baron MS. Movement disorders in the older patient: differential diagnosis and general management. Cleve Clin J Med 2005;73(3):S38-51
   Google Scholar
• Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediate-release and controlled-release carbidopa/L-dopa in PD: a 5-year randomized multicenter study. Neurology 1999;53:1012-9
   PubMed Web of Science ®Google Scholar
• Sagar KA, Symth MR. Bioavailability studies of oral dosage forms containing L-dopa and carbidopa using column-switching chromatography followed by electrochemical detection. Analyst 2000;125:439-45
   PubMed Web of Science ®Google Scholar
• Koller W, Guarnieri M, Hubble J, An open-label evaluation of the tolerability and safety of Stalevo® (carbidopa, L-dopa and entacapone) in Parkinson's disease patients experiencing wearing-off. J Neural Transm 2005;112:221-30
   PubMed Web of Science ®Google Scholar
• Piccini P, Brooks DJ, Korpela K, The catechol-o-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;68:589-94
   PubMed Web of Science ®Google Scholar
• Hauser RA. L-dopa/carbidopa/entacapone (stalevo). Neurology 2004;62:564-71
   Web of Science ®Google Scholar
• Kallioinen S, Kervinen L, Laaksonen M, L-dopa/carbidopa/entacapone pharmaceutical preparation. WO2001001984; 2001
   Google Scholar
• Olanow CW, Stocchi F. COMT inhibitors in Parkinson's disease: can they prevent and/or reverse L-dopa-induced motor complications? Neurol 2004;62:72S-81
   Web of Science ®Google Scholar
• Smith LA, Jackson MJ, Al-Barghouthy G, Multiple small doses of L-dopa plus entacapone produce continous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord 2005;20:306-14
   PubMed Web of Science ®Google Scholar
• Hauser RA, Panisset M, Abbruzzese G, Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord 2008;24:539-48
   Google Scholar
• Barone P. Clinical strategies to prevent and delay motor complications. Neurol 2003;61:S12-6
   PubMed Web of Science ®Google Scholar
• Stocchi F, Barbato L, Nordera G, Entacapone improves the pharmacokinetic and therapeutic response of controlled release L-dopa/carbidopa in parkinson's patients. J Neural Transm 2004;111:173-80
   PubMed Web of Science ®Google Scholar
• Gasser UE, Crevoisier C, Ouwerkerk M, Comparative single- and multiple-dose pharmacokinetics of L-dopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of L-dopa and benserazide in healthy subjects. Eur J Pharm Biopharm 1998;46:223-8
   PubMed Web of Science ®Google Scholar
• Chen JJ, Trombetta DP, Fernandez HH. Palliative management of Parkinson disease: focus on nonmotor, distressing symptoms. J Pharm Pract 2008;21(4):262-72
   Google Scholar
• Han C, Hsu L, Hsu AF. Combination immediate release controlled release levodopa/carbidopa dosage forms. US7094427; 2006
   Google Scholar
• Stacy M. Pharmacotherapy for advanced Parkinson's disease. Pharmacother 2000;20:8S-16S
   PubMed Web of Science ®Google Scholar
• Adler CH. Relevance of motor complications in Parkinson's disease. Neurol 2002;58:51S-56
   PubMed Web of Science ®Google Scholar
• Woitalla D, Goetze O, Kim J, L-dopa availability improves with progression of Parkinson's disease. J Neurol 2006;253:1221-6
   PubMed Web of Science ®Google Scholar
• Metman LV. Recognition and treatment of response fluctuations in Parkinson's disease: review article. Amino Acids 2002;23:141-5
   PubMed Web of Science ®Google Scholar
• Calne SM, Kumar A. Nursing care of patients with late stage Parkinson's disease. J Neurosci Nurs 2003;35:242-51
   PubMedGoogle Scholar
• Obering CD, Chen JJ Swope DM. Update on apomorphine for the rapid treatment of hypomobility (“Off”) episodes in Parkinson's disease. Pharmacother 2006;26:840-52
   PubMed Web of Science ®Google Scholar
• Weintraub D, Comella CL, Stacy H. Part 2: treatment of motor symptoms. Am J Manag Care 2008;14:S49-58
   PubMed Web of Science ®Google Scholar
• Högl B, Peralta C, Wetter TC, Effect of sleep deprivation on motor performance in patients with Parkinson's disease. Mov Disord 2001;16:616-21
   PubMed Web of Science ®Google Scholar
• Compton BJ, Solari NE, Flanagan MA. Oral delivery formulation. WO1999030690; 1999
   Google Scholar
• Remenar J, Almarsson O, Meehan AJ, Zhang Z. Pharamceutical compositions and method of using L-dopa and carbidopa. WO2005099678; 2005
   Google Scholar
• Mathur RS, Manan S, Mehta K. Carbidopa and L-dopa dispersible tablets. WO2006035414; 2006
   Google Scholar
• Iyer SS, Morgan JC, Sethi KD. Absorption of orally disintegrating carbidopa-L-dopa requires intact small bowel function. Neurol 2005;65:1507
   PubMed Web of Science ®Google Scholar
• Nausieda PA, Pfeiffer RF, Tagliati M, A multicenter, open-label, sequential study comparing preferences for carbidopa-L-dopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease. Clin Ther 2005;27:58-63
   PubMed Web of Science ®Google Scholar
• Rubin AA. Improvement in the treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-L-dopa. WO2000015197; 2000
   Google Scholar
• Descombes S, Bonnet AM, Gasser UE, Dual-release formulation, a novel principle in L-dopa treatment of Parkinson's disease. Neurol 2001;56:1239-42
   PubMed Web of Science ®Google Scholar
• Durif F, Vidailhet M, Assal F, Low-dose clozapine improves dyskinesias in Parkinson's disease. Neurol 1997;48:658-62
   PubMed Web of Science ®Google Scholar
• Cohen S, Yoram S, Levy R, Pharmaceutical composition of L-dopa ester. US5840756; 1998
   Google Scholar
• Xiang J-N, Gallop MA, Zhou CX, L-dopa prodrugs and compositions and uses thereof. US7342131; 2008
   Google Scholar
• Black KJ, Carl JL, Hartlein JM, Rapid intravenous loading of L-dopa for human research: clinical results. J Neurosci Methods 2003;127:19-29
   PubMed Web of Science ®Google Scholar
• Nyholm D, Nilsson Remahl AIM, Dizdar N, Duodenal L-dopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurol 2005a;64:216-23
   PubMed Web of Science ®Google Scholar
• Nyholm D, Jansson R, Willows T, Remahl IN. Long-term 24-hour duodenal infusion of L-dopa: Outcome and dose requirements. Neurol 2005b;65:1506-7
   PubMed Web of Science ®Google Scholar
• Mouradian MM. Should L-dopa be infused into the duodenum? Neurol 2005;64:182-3
   PubMed Web of Science ®Google Scholar
• Antonini A. Continuous dopaminergic stimulation – from theory to clinical practice. Parkinson Relat Disord 2007;13:S24-8
   PubMed Web of Science ®Google Scholar
• Benoit J, Faisant N, Venier-Julienne M, Menei P. Development of microspheres for neurological disorders: from basics to clinical applications. J Control Release 2000;65:285-96
   PubMed Web of Science ®Google Scholar
• Herrero-Vanrell R, Refojo MF. Biodegradable microspheres for vitreoretinal drug delivery. Adv Drug Deliv Rev 2001;52:5-16
   PubMed Web of Science ®Google Scholar
• Hickey T, Kreutzer D, Burgess DJ, Moussy F. Dexamethasone/PLGA microspheres for continuous delivery of an anti-inflammatory drug for implantable medical devices. Biomaterials 2002;23:1649-56
   PubMed Web of Science ®Google Scholar
• Vasir JK, Tambwekar K, Garg S. Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm 2003;255:13-32
   PubMed Web of Science ®Google Scholar
• Van Tomme SR, De Geest BG, Braeckmans K, Mobility of model proteins in hydrogels composed of oppositely charged dextran microspheres studied by protein release and fluorescence recovery after photobleaching. J Control Release 2005;110:67-78
   PubMed Web of Science ®Google Scholar
• Bubeníková S, Kalinovská L, Theiszová M, Biological tests of ofloxacin-releasing chitosan-based microspheres. J Control Release 2008;132:e22-3
   Web of Science ®Google Scholar
• Wei L, Cai C, Lin J, Chen T. Dual-drug delivery system based on hydrogel/micelle composites. Biomaterials 2009;30:2606-13
   PubMed Web of Science ®Google Scholar
• Brime B, Ballesteros MP, Frutos P. Preparation and in vitro characterization of gelatin microspheres containing L-dopa for nasal administration. J Microencapsul 2000;17:777-84
   PubMed Web of Science ®Google Scholar
• ArIca B, Kaş HS, Moghdam A, Carbidopa/L-dopa-loaded biodegradable microspheres: in vivo evaluation on experimental parkinsonism in rats. J Control Release 2005;102:689-97
   PubMed Web of Science ®Google Scholar
• Arica B, Kas HS, Sargon MF, Hincal AA. Physicochemical Characteristics of L-dopa Loaded Chitosan Microspheres for Brain Delivery. AAPS Annual Meeting (1998). Available from: http://www.aapsj.org/abstracts/AM_1998/1308.html. [Accessed 02.10.2008]
   Google Scholar
• Morrison RA, Kripalani KJ, Marino AM, Intestinal absorption of captopril and two thioester analogs in rats and dogs. Biopharm Drug Dispos 1998;18:125-39
   Web of Science ®Google Scholar
• Hoffman A, Stepensky D, Lavy E, Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms. Int J Pharm 2004;277:141-53
   PubMed Web of Science ®Google Scholar
• Streubel A, Siepmann J, Bodmeier R. Drug delivery to the upper small intestine window using gastroretentive technologies. Curr Opin Pharmacol 2006;6:501-8
   PubMed Web of Science ®Google Scholar
• Talukder R, Fassihi R. Gastroretentive delivery systems: a mini review. Drug Dev Ind Pharm 2004;30:1019-28
   PubMed Web of Science ®Google Scholar
• Klausner EA, Eyal S, Lavy E, Novel L-dopa gastroretentive dosage form: in-vivo evaluation in dogs. J Control Release 2003;88:117-26
   PubMed Web of Science ®Google Scholar
• Erni W, Held K. The hydrodynamically balanced system: a novel principle of controlled drug release. Eur Neurol 1987;27:21-7
   PubMedGoogle Scholar
• Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release 2000;63:235-59
   PubMed Web of Science ®Google Scholar
• Goole J, Vanderbist F, Amighi K. Development and evaluation of new multiple-unit L-dopa sustained-release floating dosage forms. Int J Pharm 2007;334:35-41
   PubMed Web of Science ®Google Scholar
• Waterman KC. A critical review of gastric retentive controlled drug delivery. Pharm Dev Technol 2007;12:1-10
   PubMed Web of Science ®Google Scholar
• Goole J, Amighi K, Vanderbist F. Evaluation and floating enhancement of l-dopa sustained release floating minitablets coated with insoluble acrylic polymer. London: Informa Healthcare; 2008
   Google Scholar
• Goole J, Deleuze P, Vanderbist F, Amighi K. New L-dopa sustained-release floating minitablets coated with insoluble acrylic polymer. Eur J Pharm Biopharm 2008;68:310-8
   PubMed Web of Science ®Google Scholar
• Goole J, Van Gansbeke B, Pilcer G, Pharmacoscintigraphic and pharmacokinetic evaluation on healthy human volunteers of sustained-release floating minitablets containing levodopa and carbidopa. Int J Pharm 2008;364(1):54-63
   PubMed Web of Science ®Google Scholar
• Davis SS, Wilding IR. Oral drug absorption studies: the best model for man is man! Drug Discov Today 2001;6:127-130
   PubMed Web of Science ®Google Scholar
• Paulson SK, Vaughn MB, Jessen SM, Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J Pharmacol Exp Ther 2001;297:638-45
   PubMed Web of Science ®Google Scholar
• Fotaki N, Symillides M, Reppas C. Canine versus in vitro data for predicting input profiles of l-sulpiride after oral administration. Eur J Pharm Sci 2005;26:324-33
   PubMed Web of Science ®Google Scholar
• Chen JJ, Trombetta DP, Fernandez HH. Palliative management of Parkinson disease: focus on nonmotor, distressing symptoms. J Pharm Pract 2008;21:262-72
   Google Scholar
• Davis SS. Formulation strategies for absorption windows. Drug Discov Today 2005;10:249-57
   PubMed Web of Science ®Google Scholar
• Sabel B, Dominiak P, Hauser W, L-dopa delivery from controlled-release polymer matrix: delivery of more than 600 days in vitro and 225 days of elevated plasma levels after subcutaneous implantation in rats. J Pharmacol Exp Ther 1990;255:914-22
   PubMed Web of Science ®Google Scholar
• Jackson B, Bennet DJ, Bartus RT, Emerich DF. Pulmonary delivery for L-dopa. US20040018989A1; 2004
   Google Scholar
• Bartus RT, Emerich D, Snodgrass-Belt P, A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson's disease. J Pharmacol Exp Ther 2004;310:828-35
   PubMed Web of Science ®Google Scholar
• Linazasoro G. Potential applications of nanotechnologies to Parkinson's disease therapy. Parkinson Relat Disord 2008;14:383-92
   PubMed Web of Science ®Google Scholar
• Kim TK, Kang W, Chun IK, Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems. Eur J Pharm Sci 2009;38:525-32
   Google Scholar
• Babita K, Rana V, Tiwary AK. Epidermal lipids: thermotropic behavior and role in transcutaneous permeation of L-dopa. Drug Dev Res 2004;63:190-9
   Web of Science ®Google Scholar
• Babita K, Tiwary AK. Transcutaneous delivery of L-dopa: enhancement by fatty acid synthesis inhibition. Mol Pharm 2005;2:57-63
   PubMed Web of Science ®Google Scholar
• Sudo J, Iwase H, Terui J, transdermal absorption of L-dopa from hydrogel in rats. Eur J Pharm Sci 1998;7:67-71
   PubMed Web of Science ®Google Scholar
• Fix JA, Alexander J, Cortese M, Short-chain alkyl esters of L-dopa as prodrugs for rectal absorption. Pharm Res 1989;6:501-5
   PubMed Web of Science ®Google Scholar
• Djaldetti R, Inzelberg R, Giladi N, Oral solution of L-dopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease. Mov Disord 2002;17:297-302
   PubMed Web of Science ®Google Scholar
• Bettini R, Acerbi D, Caponetti G, Influence of layer position on in vitro and in vivo release of L-dopa methyl ester and carbidopa from three-layer matrix tablets. Eur J Pharm Biopharm 2002;53:227-32
   PubMed Web of Science ®Google Scholar
• Repta AJ. Rectally absorbable form of L-dopa. US4663349; 1987
   Google Scholar
• Djaldetti R, Melamed E. Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease. Ann Neurol 1996;39:400-4
   PubMed Web of Science ®Google Scholar
• Stocchi F, Barbato L, Bramante L, Fluctuating parkinsonism: a pilot study of single afternoon dose of L-dopa methyl ester. J Neurol 1996;243:377-80
   PubMed Web of Science ®Google Scholar
• Kao HD, Traboulsi A, Itoh S, Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs. Pharm Res 2000;17:978-84
   PubMed Web of Science ®Google Scholar
• Kushnir M, Heldman E. Apparatus for the transdermal treatment of Parkinson's disease. US6746688; 2004
   Google Scholar
• Parkinson Study Group. A randomized controlled trial of etil-dopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol 2006;63:210-6
   PubMed Web of Science ®Google Scholar
• Di Stefano A, Sozio P, Iannitelli A, Maleic- and fumaric-diamides of (O,O-diacetyl)-L-dopa-methylester as anti-parkinson prodrugs in liposomal formulation. J Drug Target 2006;14(9):652-61
   PubMed Web of Science ®Google Scholar
• Eisler T, Eng N, Plotkin C, Calne DB. Absorption of L-dopa after rectal administration. Neurol 1981;31:215-7
   PubMed Web of Science ®Google Scholar
• Kreuter J. Application of nanoparticles for the delivery of drugs to the brain. Int Congr Series 2005;1277:85-94
   Google Scholar
• Mukai S, Lipsitz LA. Orthostatic hypotension. Clin Geriatr Med 2002;18:253-68
   PubMed Web of Science ®Google Scholar
• Lum ZP, Tai IT, Krestow M, Prolonged reversal of diabetic state in NOD mice by xenografts of microencapsulated rat islets. Diabetes 1991;40:1511-6
   PubMed Web of Science ®Google Scholar
• Pardridge W. Blood-brain barrier delivery. Drug Discov Today 2007;12:54-61
   Google Scholar
• Pardridge WM. Vector mediated drug delivery the brain. Adv Drug Deliv Rev 1999;36:299-321
   PubMed Web of Science ®Google Scholar
• Calvo P, Gouritin B, Chacun H, Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 2001;18:1157-66
   PubMed Web of Science ®Google Scholar
• Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 1996;93:14164-9
   PubMed Web of Science ®Google Scholar
• Naoi M, Eto Y. Liposome targeting to mouse brain: mannose as a recognition marker. Biochem Biophys Res Commun 1988;153:1038-44
   PubMed Web of Science ®Google Scholar
• Nimesh S, Manchanda R, Kumar R, Preparation, characterization and in vitro drug release studies of novel polymeric nanoparticles. Int J Pharm 2006;323:146-52
   PubMed Web of Science ®Google Scholar
• Soppimath K, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001;70:1-20
   PubMed Web of Science ®Google Scholar
• Italia JL, Bhatt DK, Bhardwaj V, PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to sandimmune neoral®. J Control Release 2007;119:197-206
   PubMed Web of Science ®Google Scholar
• Di Stefano A, Sozio P, Iannitelli A, Serafina Cerasa L. New drug delivery strategies for improved Parkinson's disease therapy. Expert Opin Drug Deliv 2009;6:389-404
   PubMed Web of Science ®Google Scholar
• Rekas A, Lo V, Gadd GE, PAMAM dendrimers as potential agents against fibrillation of a-synuclein, a Parkinson's disease-related protein. Macromol Biosci 2009;9:230-8
   PubMed Web of Science ®Google Scholar
• Aubin N, Curet O, Deffois A, Carter C. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem 1998;71:1635-42
   PubMed Web of Science ®Google Scholar
• Bharath S, Hsu M, Kaur D, Glutathione, iron and Parkinson's disease. Biochem Pharmacol 2002;64:1037-48
   PubMed Web of Science ®Google Scholar
• Bridge MH, Williams E, Lyons ME, Electrochemical investigation into the redox activity of Fe(II)/Fe(III) in the presence of nicotine and possible relations to neurodegenerative diseases. Biochim Biophys Acta Mol Basis Dis 2004;1690:77-84
   PubMed Web of Science ®Google Scholar
• Brotchie M, Lee J, Venderova K. Levodopa-induced dyskinesia in Parkinson's disease. J Neural Transm 2005;112:359-391
   PubMed Web of Science ®Google Scholar
• Mandel S, Weinreb O, Amit T, Youdim MBH. Mechanism of neuroprotective action of the anti-parkinson drug rasagiline and its derivatives. Brain Res Rev 2005;48:379-87
   PubMed Web of Science ®Google Scholar
• Schrag A, Schott JM. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol 2006;5:355-63
   PubMed Web of Science ®Google Scholar
• Somani PM. Parkinsons's disease. Latest Rev 2008;6:3048
   Google Scholar
• Fahn S. The history of dopamine and L-dopa in the treatment of Parkinson's disease. Mov Disord 2008;23:S497-508
   PubMed Web of Science ®Google Scholar